Thank You! Your Voices Were Heard
Thank you for lending your voice and taking action on behalf of those living with pulmonary arterial hypertension (PAH) across Canada! Together, we were able to help PAH patients gain access to Uptravi (selexipag) via public funding.
Uptravi is now accessible via public funding in every province and to the vast majority of Canadians living with PAH.
The Pulmonary Hypertension Association of Canada (PHA Canada), along with Scleroderma Canada, is driven by the belief that all PAH patients—no matter their financial situation, province of residence, or private insurance coverage—should have equitable access to optimal treatment. PAH is a highly individualized illness, and specialized PAH physicians require the flexibility to prescribe any Health Canada-approved treatment they believe will result in the best possible short and long-term outcomes for their patients.
Your Help Is Still Needed
We still need your help to ensure that Canadians affected by PAH have access to any and all Health Canada-approved treatments.
The PAH community is hopeful that provincial and territorial governments will continue to support PAH patients and fund all remaining Health Canada-approved treatments, such as Opsumit (macitentan), which is currently accessible through public funding only in Québec.
Please stay tuned to our social channels and this website to learn how you can take action for PAH once again.